Similar articles

• In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

  Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr. Song DG, et al. Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5. Cancer Res. 2011. PMID: 21546571 Free PMC article.
• Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.

  Liu G, Luo P. Liu G, et al. Front Immunol. 2023 Jun 2;14:1208788. doi: 10.3389/fimmu.2023.1208788. eCollection 2023. Front Immunol. 2023. PMID: 37334375 Free PMC article. Review.
• T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3ζ show enhanced antitumor activity.

  Teng X, Rong Z, Li S, Yang W, Lu Z. Teng X, et al. Immunol Cell Biol. 2023 May;101(5):458-464. doi: 10.1111/imcb.12634. Epub 2023 Mar 10. Immunol Cell Biol. 2023. PMID: 36811384
• In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.

  Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, Jin T, Xie R, Wei B, Chen J, Fang H, Han X, Rohrs JA, Bryson P, Liu Y, Li QJ, Zhu B, Wang P. Cheng Z, et al. Mol Ther. 2018 Apr 4;26(4):976-985. doi: 10.1016/j.ymthe.2018.01.022. Epub 2018 Feb 2. Mol Ther. 2018. PMID: 29503204 Free PMC article. Clinical Trial.
• New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.

  Etxeberria I, Glez-Vaz J, Teijeira Á, Melero I. Etxeberria I, et al. ESMO Open. 2020 Jul;4(Suppl 3):e000733. doi: 10.1136/esmoopen-2020-000733. ESMO Open. 2020. PMID: 32611557 Free PMC article. Review.